title: Induction of propranolol metabolism in isolated rats hepatocytes treated by di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate (MEHP).
abstract: Blood lines of polyvinyl chloride (PVC) for hemodialysis usually contain di(2-ethylhexyl) phthalate (DEHP) as a plasticizer. Previous studies show that 1 mg/kg of this plasticizer can leach into the blood during one dialysis session. It is rapidly metabolized in the liver. Mono(2-ehtylhexyl) phthalate (MEHP), its main metabolite can be detected as well. After oral administration to rodents, both compounds caused a variety of adverse biological effects such as testicular atrophy, peroxisome proliferation and hepatic peroxisomal enzyme induction. Male wistar rats were treated intraperitoneally by DEHP and MEHP using twice the dose of that involved in human exposure during a dialysis session. Propranolol metabolism by hepatocytes was investigated after fresh isolation from treated and untreated rats by means of reverse phase HPLC. The choice of propranolol as a substrate was made because of its rather quick liver metabolisation. Phenobarbital was chosen in the study as a reference of enzymatic inducer to evaluate the inducing effect of DEHP and MEHP. Propranolol was metabolized by the hepatocytes of both treated and untreated rats. Hepatocytes isolated from rats treated by phenobarbital, MEHP and DEHP were shown to have a higher speed constant of metabolism indicating a rapid metabolism of propranolol. Under these conditions, in fact, propranolol metabolisation was found to be respectively 6, 2.7, 2 times faster than the propranolol metabolisation of untreated rats. The hypothesis that DEHP and MEHP are enzymatic inducers, particularly cytochrome P450 (CYP) inducers of the xenobiotics metabolism on the intact liver after IP administration has become been found to be valid. The results obtained in this study confirm the value of isolated hepatocytes as an in vivo drug metabolism predictive model.
authors.affiliation: Laboratoire de Pharmacologie, Pharmacocinétique et Pharmacie Clinique, Faculté des Sciences Pharmaceutiques et Biologiques, Lille, France.
authors.forename: K
authors.initials: K
authors.lastname: Kambia
authors.forename: T
authors.initials: T
authors.lastname: Dine
authors.forename: B
authors.initials: B
authors.lastname: Gressier
authors.forename: B
authors.initials: B
authors.lastname: Benaji
authors.forename: M A
authors.initials: MA
authors.lastname: Faouzi
authors.forename: T
authors.initials: T
authors.lastname: Dupin-Spriet
authors.forename: M
authors.initials: M
authors.lastname: Luyckx
authors.forename: C
authors.initials: C
authors.lastname: Brunet
mesh_terms: D000818:Animals; D004051:Diethylhexyl Phthalate / Q000031:analogs & derivatives* / Q000494:pharmacology*; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D011433:Propranolol / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D011433:Propranolol; D004051:Diethylhexyl Phthalate; C016599:mono-(2-ethylhexyl)phthalate